Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amorcyte, Inc.

Latest From Amorcyte, Inc.

Deals Shaping the Medical Industry (09/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

NeoStem raises $16.5M as it continues to shift its focus to cell therapy

NeoStem, the New York-based cell therapy company, plans to raise $16.5 million through the sale of 13.8 million share-and-warrant units at $1.20 per unit, a considerable discount to the 18 July stock closing price of $1.32.

Cardiovascular China

NeoStem expands into cardiovascular space with $18 million Amorcyte buy

Stem cell specialist NeoStem has agreed to purchase Amorcyte, a cardiovascular stem cell therapy developer, a move which will give it access to the cardiovascular therapy market. Amorcyte's lead product, AMR-001, is about to start a Phase II trial in acute myocardial infarction (AMI).

Cardiovascular China

New Stem Cell Therapies

Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.

BioPharmaceutical Strategy
See All

Company Information